Dr. Molly Shoichet, Chief Scientific Officer, Co-Founder of AmacaThera and University of Toronto Professor said, “We are proud to be confirming the clinical success of AmacaGel™ which serves as the launch pad for improving the efficacy of antibodies, mRNA, small molecules, proteins amongst other therapeutic modalities. It’s exciting to see AmacaThera advance this technology into the clinic in such a short time.”
AmacaThera’s pipeline development will progress throughout 2023 with AMT-143 Phase 1 efficacy studies in post-operative pain alongside the rapid pre-clinical advancement of AMT-456 for multi-modal treatment of unmet medical needs in oncology.
About AmacaGel™
AmacaGel™, AmacaThera’s platform technology, is a fast-gelling, thermoresponsive hydrogel that has been designed to both liquify under shear force, enabling conventional syringe delivery, and then gel at body temperature, thereby forming a depot at the injection site.
About AmacaThera
AmacaThera Inc, a clinical-stage company transforming therapeutics to make a difference in patient health. AmacaGel™, our unique, injectable hydrogel platform provides localized sustained drug delivery for improved patient outcomes across multiple therapeutic areas, including post-surgical pain management, cancer and other hard-to-reach unmet medical needs.
For further information:
Mike Foorer
VP Business Development & General Manager
mike_foorer at amacathera dot ca